Methods for treating angina with ranolazine
US6479496B1 · kind B1 · utility
28Cited by
2References
10Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 8, 2000 |
| Grant date | Nov 12, 2002 |
| Priority date | — |
| Expiry date | Mar 8, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2054
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 850 and 4000 ng base/mL.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.